Press coverage about Sunshine Heart (NASDAQ:CHFS) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sunshine Heart earned a news impact score of 0.05 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.7798947244882 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Sunshine Heart (NASDAQ:CHFS) traded down $0.57 during trading on Thursday, hitting $3.22. 1,206,600 shares of the stock were exchanged, compared to its average volume of 177,444. Sunshine Heart has a 52 week low of $3.11 and a 52 week high of $576.00.
A number of equities analysts have commented on CHFS shares. ValuEngine raised shares of Sunshine Heart from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research raised shares of Sunshine Heart from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research report on Wednesday.
ILLEGAL ACTIVITY WARNING: “Sunshine Heart (CHFS) Earning Somewhat Positive Press Coverage, Report Finds” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/12/07/sunshine-heart-chfs-earning-somewhat-positive-press-coverage-report-finds.html.
Sunshine Heart Company Profile
CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
Receive News & Ratings for Sunshine Heart Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart Inc and related companies with MarketBeat.com's FREE daily email newsletter.